Sutro Biopharma, Inc.
STRO
$0.81
$0.00470.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 66.43M | 62.04M | 160.96M | 169.36M | 154.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.43M | 62.04M | 160.96M | 169.36M | 154.07M |
| Cost of Revenue | -42.09M | -41.20M | 12.47M | -3.97M | -24.39M |
| Gross Profit | 108.53M | 103.24M | 148.48M | 173.32M | 178.46M |
| SG&A Expenses | 49.01M | 48.45M | 56.23M | 57.17M | 59.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 295.77M | 300.50M | 291.00M | 275.50M | 257.70M |
| Operating Income | -229.33M | -238.45M | -130.04M | -106.14M | -103.63M |
| Income Before Tax | -242.85M | -225.10M | -108.14M | -106.80M | -97.16M |
| Income Tax Expenses | 2.36M | 2.36M | 15.82M | 17.65M | 17.80M |
| Earnings from Continuing Operations | -245.22 | -227.46 | -123.95 | -124.45 | -114.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -245.22M | -227.46M | -123.95M | -124.45M | -114.96M |
| EBIT | -229.33M | -238.45M | -130.04M | -106.14M | -103.63M |
| EBITDA | -221.98M | -231.24M | -122.96M | -99.12M | -96.67M |
| EPS Basic | -2.98 | -3.01 | -1.62 | -1.84 | -1.89 |
| Normalized Basic EPS | -1.90 | -2.12 | -1.19 | -1.13 | -1.21 |
| EPS Diluted | -2.98 | -3.01 | -1.62 | -1.84 | -1.89 |
| Normalized Diluted EPS | -1.90 | -2.12 | -1.19 | -1.13 | -1.21 |
| Average Basic Shares Outstanding | 328.89M | 307.24M | 285.70M | 264.25M | 243.37M |
| Average Diluted Shares Outstanding | 328.89M | 307.24M | 285.70M | 264.25M | 243.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |